Amylyx Reports Positive Phase 3 Trial Results for GLP-1 Drug Avexitide
Amylyx (AMLX) reported positive results from its late-stage clinical trial of avexitide, a first-in-class GLP-1 receptor antagonist designed to treat post-bariatric hypoglycemia. The Lucidity trial showed a 55% reduction in hypoglycemic events and met all primary and secondary endpoints, including safety criteria. This milestone positions the company for an FDA submission by year-end with plans for commercial launch in early 2027. The drug currently has no approved competitors and holds both Breakthrough Therapy and Orphan Drug designations from the FDA. Amylyx's stock surged following the announcement, trading at nearly three times its price compared to earlier this year. The company also reported a strong balance sheet with funding extending into 2028. Analysts view avexitide as a high-potential treatment in an underserved market and maintain a 'Strong Buy' consensus rating for AMLX, suggesting further upside potential.
Tickers: $AMLX
Topics: GLP-1_receptor_antagonist phase_3_trials stock_movement